Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers-Reference-Cited by-同舟云学术

Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers

Published:2018-01 Issue:1 Volume:11 Page:
ISSN:1941-7713
Container-title:Circulation: Cardiovascular Quality and Outcomes
language:en
Short-container-title:Circ Cardiovasc Qual Outcomes

Author:

Doshi Jalpa A.¹,Puckett Justin T.¹,Parmacek Michael S.¹,Rader Daniel J.¹

Affiliation:

1. From the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Dr Doshi, J.T. Puckett, Dr Parmacek, and Dr Rader) and the Leonard Davis Institute of Health Economics, Philadelphia (Dr Doshi).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Reducing LDL with PCSK9 Inhibitors — The Clinical Benefit of Lipid Drugs

2. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

3. Silverman ED. How much?! Those new cholesterol drugs could cost $23 billion a year. The Wall Street Journal . June 9 2015. Available at: http://blogs.wsj.com/pharmalot/2015/06/09/how-much-those-new-cholesterol-drugs-could-cost-23-billion-a-year/. Accessed April 5 2017.

4. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012

5. Tice JA Ollendorf DA Cunningham C Pearson SD Kazi DS Coxson PG. PCSK9 inhibitors for treatment of high cholesterol: effectiveness value and value-based price benchmarks. Institute for Clinical and Economic Review. Available at: https://icer-review.org/wp-content/uploads/2016/01/Final-Report-for-Posting-11-24-15-1.pdf. Accessed April 5 2017.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications;American Journal of Cardiovascular Drugs;2024-08-13

2. Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage;BMJ;2024-03-07

3. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-07

4. Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists;The American Journal of Managed Care;2023-04-20

5. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic;Journal of Clinical Lipidology;2023-01